"Now the only option will be to find the best possible deal on traditional forms of the drugs," says NYU's Alexandra Sowa, MD ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

INDIANAPOLIS: Drugmaker Eli Lilly and Company’s SVP and chief communications officer, Kathryn Beiser, has resigned. Beiser ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

In the past year, treatments such as Wegovy, Mounjaro and Zepbound have become household names. But there are many questions ...

Two Sigma Investments, a tech-powered hedge fund run by data-loving geniuses, recently upped its bet on pharmaceutical ...

TikTok user Bridget, 37, lost over 100 lbs. after taking a weight loss medication and making lifestyle changes. But the body shaming hasn't stopped.

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Equinox's GLP-1 protocol is considered a framework for people taking the drugs, one that addresses workout intensity, ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...